Home
overview

Molecular diagnostics are a major breakthrough in medical science and as such great things are predicted for the development and use of new therapeutics, based on these testing approaches, over the next few years. Following the success of last year’s event, SMi will be bringing together leading industry experts to explore the current and future opportunities within molecular diagnostics and strategies for exploiting them in both a clinical and R&D setting. This event will provide you with a good competitive assessment of the important molecular diagnostic markets, including updates in major market trends, forecasts and regulations and the chance to hear case studies exploring key clinical applications. You will also have the opportunity to evaluate the latest technology trends shaping the industry, drawing on new product ideas and the ability to assess your current R&D investment or select your next acquisition target/collaboration.

A unique opportunity to learn from leading industry experts including:

Stephen Lee, Principle Medical Device Specialist, Medicines & Healthcare products Regulatory Agency (MHRA)

Dr Chris Chamberlain, Global Head, Medical Genetics, Roche

Dr John Harvey, Head, Molecular Genetics, Salisbury Health Care NHS Trust

Dr Raimund Sterz, Medical Director, Health Economics & Outcomes Research, Abbott

Dr Paul Cload, Strategic Marketing Leader, Cardiology, GE Healthcare

Elodie Kazek, Director, Molecular Diagnostics, bioMerieux

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Stephen Little

Stephen Little, Chief Executive Officer, DxS Ltd

9:50 PERSONALISED MEDICINE FOR 2005-2006

Paul Cload

Paul Cload, Strategic Marketing Leader, Cardiology, GE Healthcare

  • How personalised medicine is impacting the market
  • Changing business dynamics and models
  • Recent advancements in genome analysis
  • The limitations and restraints that apply
  • What will it take to reach clinical convergence?
  • The future direction of molecular diagnostics
  • 10:30 Morning Coffee

    11:00 EMERGING INFECTIOUS DISEASES

    Elodie Kazek

    Elodie Kazek, Marketing Director, Molecular Diagnostics, bioMerieux S A

  • Commercially available molecular diagnostic tests
  • Projected use of molecular diagnostics for infectious disease testing 2005-2015
  • Issues in access and convenience of applications
  • Continuing innovation and quality in technology development
  • Recent progress and future predictions
  • 11:40 INFORMED PRESCRIPTIVE CHOICE

    Chris Chamberlain

    Chris Chamberlain, Global Head, Medical Genetics , Roche

  • The diagnostic deconstruction of complex diseases
  • Recognising and achieving business value from diagnostic practice in drug development
  • The evolving regulatory environment for genomic data
  • Proving the biomarker paradigm…the role of genetics and genomics
  • Shaping future medicine through prescriptive choice
  • 12:20 Networking Lunch

    14:00 GENETIC PROFILING TESTS FOR COMPLEX DISEASES

    Jan Mous

    Jan Mous, President & CEO, IntegraGen SA

  • Disease gene network discovery
  • Disease risk assessment
  • Molecular genotyping
  • Clinical validation
  • Genetic profiling for therapy selection
  • Genethics
  • 14:40 THE TESTING ENVIRONMENT

    John Harvey

    John Harvey, Head, Molecular Genetics, Salisbury Health Centre NHS Trust

  • A month in the life of an NHS molecular diagnostic laboratory
  • Fast throughput or high throughput?
  • Platforms for future needs
  • Sample tracking and the future direction of testing environments
  • 15:20 REGULATION IN THE EU

    Stephen Lee

    Stephen Lee, Principle Medical Device Specialist, Medicines & Healthcare products Regulatory Agency (MHRA)

  • IVD regulation and its impact
  • MHRA role in IVD regulation
  • Vigilance reporting and investigation
  • Common compliance issues
  • 16:00 Chairman’s Closing Remarks

    16:10 Networking Drinks Reception Sponsored by IntegraGen

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Stephen Little

    Stephen Little, Chief Executive Officer, DxS Ltd

    9:10 MOLECULAR DIAGNOSTIC REGULATION IN THE US

    Thomas Soriano

    Thomas Soriano, President & Chief Executive Officer, Diagnostic Oncology CRO Inc

  • An FDA overview
  • Understanding the recent developments
  • Where do the future issues lie for molecular diagnostics?
  • Forthcoming initiatives and their impact on the industry
  • Vile gossip
  • 9:50 THE MIXED ECONOMY IN HEALTHCARE AND RELATED SERVICES

    Thomas Mann

    Thomas Mann, Managing Director, Direct Health First

  • Opportunities for private sector investment in public sector provision
  • Plurality of provision
  • The strengths of the public sector
  • Competition and value for money
  • Political risks
  • Devolution and central leadership
  • Capital investment and revenue opportunities
  • Public expectations and patient choice
  • 10:30 Morning Coffee

    11:00 AN EU PERSPECTIVE ON PRICING AND REIMBURSEMENT IN THE MOLECULAR DIAGNOSTICS MARKET

    Raimund Sterz

    Raimund Sterz, Medical Director, Health Economics & Outcomes Research, Abbott GmbH & Co KG

  • Reimbursement strategies – what to consider
  • Providing clinical and economic effectiveness
  • Identifying the payers and budget holders
  • Demonstrating cost saving and health benefits of early detection through funding studies
  • Integrated disease management strategies
  • 12:20 Networking Lunch

    14:00 PROGRESS TOWARD DIAGNOSTIC APPLICATIONS OF ARRAY CGH

    Edward Chait

    Edward Chait, Chief Executive Officer, Spectral Genomics, Inc.

  • Detection of genetic disease
  • Prognosis, diagnosis and stratification in cancer
  • Predicting outcomes in cancer
  • Human large copy number variations
  • 14:40 GLOBAL PATENTING STRATEGIES

    Agnieszka Jankowska

    Agnieszka Jankowska, Founder & Managing Director, Akonsult

  • The need for patenting in global diagnostic markets
  • Minimising the costs of implementation
  • Maximising product and technology value
  • Overcoming counterfeit problems
  • An overview of what will change for diagnostics companies
  • 15:20 SOLID PHASE MATRICES FOR SIMPLIFIED SAMPLE COLLECTION, TRANSPORT AND PREPARATION

    Kevin Jones

    Kevin Jones, Technical Marketing Manager, Diagnostics, Whatman

  • Why we need to improve sample collection and processing in molecular diagnostics
  • FTA, enables samples to be transported and purified in any location
  • Filter plates can improve speed of sample processing and also sensitivity of molecular diagnostic assays
  • The ease of sample collection and processing using FTA and plates can improve
  • +

    The Grange Holborn Hotel

    50-60 Southampton Row
    London WC1B 4AR
    United Kingdom

    The Grange Holborn Hotel

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.